Jesse Simmers
About Jesse Simmers
Jesse Simmers is the AVP of IT & Facilities at Ocugen, known for implementing advanced computer technologies and designing the company's facility in Malvern, PA.
Jesse Simmers: AVP, IT & Facilities at Ocugen
Jesse Simmers holds the position of Associate Vice President (AVP) of IT and Facilities at Ocugen. In this role, Jesse oversees the integration of advanced technological solutions within the company’s operational infrastructure. His responsibilities also include ensuring the security and efficiency of data management systems, contributing significantly to the organization's IT strategies.
Jesse Simmers' Experience with Consulting
Before assuming his current role, Jesse Simmers began his tenure at Ocugen as a consultant. His expertise spans computer systems, data management, cybersecurity, and web development. During this period, he provided pivotal support in enhancing Ocugen's technological framework, ensuring robust and secure IT operations.
Jesse Simmers' Contributions to Facility Design in Malvern, PA
Jesse Simmers played a crucial role in designing Ocugen's newest facility located in Malvern, PA. His input was instrumental in integrating the latest computer-related technologies within the building. This included the deployment of advanced systems that improved workflows and upgraded employee workstations, thereby fostering a modern and efficient work environment.
Implementation of High-Tech Solutions by Jesse Simmers
In his capacity at Ocugen, Jesse Simmers has been responsible for implementing cutting-edge technologies across the company’s infrastructure. This encompassed the installation and optimization of advanced computer systems and the enhancement of data security measures, ensuring the organization's technological edge and operational security.
Development of the Multi-Luminance Mobility Test for OCU400
Jesse Simmers developed and deployed the Multi-Luminance Mobility Test, a critical component in the clinical trials for OCU400. This test plays a significant role in the evaluation phase of this therapeutic candidate, underscoring Jesse's vital contributions to Ocugen's clinical research and development efforts.